Vasodrive Ap Hydrolyzed Casein Lactotripeptides
Also known as: AmealPeptide, lactotripeptides, Valyl-Prolyl-Proline, Isoleucyl-Prolyl-Proline, VasoDrive-AP
Overview
VasoDrive-AP, a proprietary blend derived from milk protein casein, contains two primary lactotripeptides: Valyl-Prolyl-Proline (VPP) and Isoleucyl-Prolyl-Proline (IPP). These peptides are produced through enzymatic hydrolysis and are recognized for their ability to enhance cardiovascular health by improving arterial elasticity and reducing blood pressure levels. The tripeptides are stable during digestion, allowing for their absorption in their intact form, thereby preserving their bioactive properties. Over 30 studies, including systematic reviews and randomized controlled trials, substantiate the effectiveness of VasoDrive-AP in managing blood pressure and supporting exercise recovery. Its use is prevalent among individuals seeking improvement in vascular function and overall cardiovascular support.
Benefits
VasoDrive-AP has several scientifically supported benefits, primarily in reducing blood pressure. Systematic reviews indicate a significant reduction in systolic blood pressure (SBP) by approximately 7.8 to 11.2 mmHg after consistent supplementation over periods of 1-4 weeks. The effects appear to be particularly pronounced in individuals with mild hypertension, offering a reduction of -8.35 mmHg in hypertensive patients compared to normotensive individuals. Additionally, VasoDrive-AP promotes recovery from exercise by reducing muscle soreness and enhancing endothelial function during training cycles. It shows potential in individuals with high-normal blood pressure, providing both cardiovascular benefits and performance enhancements.
How it works
VasoDrive-AP operates primarily through the inhibition of the angiotensin-converting enzyme (ACE), which plays a crucial role in the regulation of blood vessel constriction. By blocking ACE activity, VasoDrive-AP enhances the activity of endothelial nitric oxide synthase (eNOS), leading to increased nitric oxide production and resultant vasodilation. This process effectively enhances arterial elasticity and lowers blood pressure. The absorption of the tripeptides is efficient due to their stable structure, allowing them to remain intact during the digestive process and interact effectively with biological systems.
Side effects
The safety profile of VasoDrive-AP is very favorable, with no significant side effects reported in clinical studies. It is classified as Generally Recognized As Safe (GRAS) by the FDA and is also certified as Food for Specified Health Uses (FOSHU). No common side effects (greater than 5%) have been documented; similarly, no specific uncommon (1-5%) or rare side effects (under 1%) have been noted. There is no substantial evidence of drug interactions, though individuals on other cardiovascular medications should use caution. While contraindications are generally absent, individuals with severe cardiovascular conditions are advised to consult healthcare professionals before use. Additionally, it is safe for those with lactose intolerance due to minimal lactose content (less than 0.05%).
Dosage
Recommended dosing for VasoDrive-AP typically ranges from 3 to 10 mg per day, based on the combined levels of the active tripeptides IPP and VPP. Clinical studies have identified effective daily doses between 2.6 mg and 5.6 mg to achieve desired outcomes. There is currently no established maximum safe dose; however, doses exceeding 10 mg have not been thoroughly examined for safety. VasoDrive-AP can be consumed at any time, though consistency in daily intake is suggested to maximize benefits. It is available in various forms, including dietary supplements and functional beverages, ensuring proper absorption due to the integrity of the tripeptides’ structure.
FAQs
Is VasoDrive-AP safe?
Yes, it is generally safe with no significant side effects reported in clinical trials.
When should I take VasoDrive-AP?
You can take it at any time, but consistent daily dosing is recommended for the best results.
How soon can I expect results?
Users often see a reduction in blood pressure and improvements in arterial elasticity within 3-4 weeks of supplementation.
Can VasoDrive-AP replace my medications?
No, it is not a substitute for prescribed treatments but can complement a health regimen.
Research Sources
- https://www.maypro.com/products/vasodrive-ap – This source provides an overview of VasoDrive-AP, including its benefits related to cardiovascular health and evidence supporting its use.
- https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/lactotripeptides-and-antihypertensive-effects-a-critical-review/C48DF5C7502E4C5EB17679A621A9EFE3 – A critical review detailing the antihypertensive effects of lactotripeptides, summarizing significant blood pressure reduction findings from multiple studies.
- https://blogs.priceplow.com/supplement-news/core-nutritionals-pump/fun-sweets-cotton-candy-vasodrive-ap – This blog discusses consumer products featuring VasoDrive-AP and highlights its application in functional beverages aimed at enhancing cardiovascular support.
- https://eu-assets.contentstack.com/v3/assets/blt2183a7e3152cc969/blt26a28d1863862abd/6568d9f302b9ac040a33ff21/NPI-IG-MayproVaso-1223.pdf – This document outlines further insights into VasoDrive-AP, including efficacy and nutritional applications in cardiovascular health.
- https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0142235 – A randomized controlled trial examining the effects of VasoDrive-AP on blood pressure, providing strong evidence for its antihypertensive effects across populations.